Case Report: Dupilumab Successfully Controls Severe Eczema in a Child With Elevated IgE Levels and Recurrent Skin Infections.

Authors

Tejas P Joshi
Sara Anvari
Meera R Gupta
Carla M Davis
Joud Hajjar

Publication Date

1-1-2021

Journal

Frontiers in Pediatrics

DOI

10.3389/fped.2021.646997

PMID

34660469

PMCID

PMC8511520

PubMedCentral® Full Text Version

Post-print

Published Open-Access

no

Keywords

hyper-IgE syndrome, dupilumab, severe eczema, primary immunodeficencies, pediatrics-children

Abstract

The efficacy of dupilumab in pediatric patients with severe eczema presenting in the setting of elevated immunoglobulin E (IgE) levels and recurrent bacterial skin infections is not well-understood. Here we present the case of a child with elevated IgE levels in whom dupilumab treatment led to remarkable control of his eczema and recurrent skin infections. We also review the use of dupilumab in other patients with molecularly proven cases of hyper IgE (HIGE) syndrome. Our case supports the notion that dupilumab may have a seminal application in treating severe eczema that occurs in the setting of elevated IgE levels and recurrent bacterial skin infections.

Comments

Associated Data